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Constitutive genetic deletion of the growth regulator Nogo-A
induces schizophrenia-related endophenotypes
Abstract
The membrane protein Nogo-A, which is predominantly expressed by oligodendrocytes in the adult
CNS and by neurons mainly during development, is well known for limiting neurite outgrowth and
regeneration in the injured mammalian CNS. In addition, it has recently been proposed that abnormal
Nogo-A expression or Nogo receptor (NgR) mutations may confer genetic risks for neuropsychiatric
disorders of presumed neurodevelopmental origin, such as schizophrenia. We therefore evaluated
whether Nogo-A deletion may lead to schizophrenia-like abnormalities in a mouse model of genetic
Nogo-A deficiency. Here, we show that systemic, lifelong knock-out of the Nogo-A gene can lead to
specific behavioral abnormalities resembling schizophrenia-related endophenotypes: deficient
sensorimotor gating, disrupted latent inhibition, perseverative behavior, and increased sensitivity to the
locomotor stimulating effects of amphetamine. These behavioral phenotypes were accompanied by
altered monoaminergic transmitter levels in specific striatal and limbic structures, as well as changes in
dopamine D2 receptor expression in the same brain regions. Nogo-A deletion was further associated
with elevated expression of growth-related markers. In contrast, acute antibody-mediated Nogo-A
neutralization in adult wild-type mice failed to produce such phenotypes, suggesting that the phenotypes
observed in the knock-out mice might be of developmental origin, and that Nogo-A normally subserves
critical functions in neurodevelopment. This study provides the first experimental demonstration that
Nogo-A bears neuropsychiatric relevance, and alterations in its expression may be one etiological factor
in schizophrenia and related disorders.
Behavioral/Systems/Cognitive
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Themembrane protein Nogo-A, which is predominantly expressed by oligodendrocytes in the adult CNS and by neuronsmainly during
development, is well known for limiting neurite outgrowth and regeneration in the injuredmammalian CNS. In addition, it has recently
been proposed that abnormal Nogo-A expression or Nogo receptor (NgR) mutations may confer genetic risks for neuropsychiatric
disorders of presumed neurodevelopmental origin, such as schizophrenia.We therefore evaluated whether Nogo-A deletionmay lead to
schizophrenia-like abnormalities in amousemodel of genetic Nogo-A deficiency. Here, we show that systemic, lifelong knock-out of the
Nogo-A gene can lead to specific behavioral abnormalities resembling schizophrenia-related endophenotypes: deficient sensorimotor
gating, disrupted latent inhibition, perseverative behavior, and increased sensitivity to the locomotor stimulating effects of amphet-
amine. These behavioral phenotypes were accompanied by altered monoaminergic transmitter levels in specific striatal and limbic
structures, aswell as changes in dopamineD2 receptor expression in the samebrain regions.Nogo-Adeletionwas further associatedwith
elevated expression of growth-related markers. In contrast, acute antibody-mediated Nogo-A neutralization in adult wild-type mice
failed to produce suchphenotypes, suggesting that the phenotypes observed in the knock-outmicemight be of developmental origin, and
that Nogo-A normally subserves critical functions in neurodevelopment. This study provides the first experimental demonstration that
Nogo-A bears neuropsychiatric relevance, and alterations in its expression may be one etiological factor in schizophrenia and related
disorders.
Introduction
Nogo-A is well known for its crucial role as a myelin-associated
inhibitor of regenerative fiber growth and structural plasticity in
the injured adult CNS (Schwab, 2004; Yiu and He, 2006). In the
intact adult CNS, Nogo-A acts as a suppressor of growth and
sprouting, thus stabilizing the wiring of the adult CNS (Buffo et
al., 2000; Bareyre et al., 2002). Nogo-A is not only expressed in
oligodendrocytes, but it is also present in subsets of neurons
(Huber et al., 2002; Wang et al., 2002). Neuronal Nogo-A is es-
pecially highly expressed in the fetal and early postnatal brain and
is downregulated in most anatomical structures in adulthood,
except in some regions of high plasticity (e.g., hippocampus), in
which neuronal Nogo-A expression remains high (Huber et al.,
2002). Nogo-Amight therefore assume critical control over neu-
rodevelopmental processes as well as neural plasticity events. A
recent report has emphasized Nogo’s possible involvement in
cortical development and neuronal maturation (Mingorance-Le
Meur et al., 2007). Although controversial, human postmortem
and genetic linkage studies have implicatedNogo-A and its chro-
mosomal location in several neuropsychiatric disorders with a
presumed neurodevelopmental origin, namely schizophrenia
and bipolar disorder (Coon et al., 1998; Shaw et al., 1998;
Novak et al., 2002; Tan et al., 2005). Moreover, Nogo receptor
1 (RTN4R, NgR1), a putative receptor subunit for Nogo-A, is
encoded by a gene located on chromosome 22q11, which is a
hotspot for genetic predisposition in schizophrenia (Liu et al.,
2002). Recently, several NgR1 mutations have also been iden-
tified in schizophrenic patients (Sinibaldi et al., 2004; Hsu et
al., 2007; Budel et al., 2008).
Schizophrenia is a severe and chronic neuropsychiatric disor-
der with a presumed etiology in abnormal neurodevelopment
attributable to combinatorial effects of environmental and genetic
risk factors (Harrison, 1997; Lewis and Levitt, 2002; Rapoport et al.,
2005). Indeed, various genetic linkage and association studies
have identified genomic regions that may harbor schizophrenia
susceptibility genes (Harrison and Weinberger, 2005; Ross et al.,
2006). Mouse deletion models of such genes are indispensable in
characterizing their function at the system level and their poten-
tial contribution to disease pathophysiology in terms of the scope
of cellular pathways, neural circuits, and behavior (Arguello and
Gogos, 2006; Chen et al., 2006). Here, a mouse model of consti-
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tutive genetic Nogo-A deficiency was evaluated in a comprehensive
series of behavioral tests with specific relevance to schizophrenia
pathopsychology. Following the demonstration of multiple
schizophrenia-like behavioral abnormalities in Nogo-A-deficient
mice, we further characterized the concomitant alterations in
brain neurotransmitters and specific markers by neurochemical
and immunohistochemical analyses, focusing in particular on
brain regions implicated in the pathophysiology of schizophre-
nia. Finally, we investigated whether the brain and behavioral
aberrations identified in Nogo-A-deficient mice could also be
induced by antibody-mediated Nogo-A suppression in adult
wild-type mice, as the first test of whether lifelong Nogo-A defi-
ciency since early life was necessary for the emergence of the
Nogo-A knock-out phenotypes.
Materials andMethods
Animals
Subjects were all 2- to 4-month-old male mice on a C57BL/6J genetic
background. They comprised Nogo-A knock-out (Nogo-A/) and
wild-type (Nogo-A/) littermates. Full details of the generation of the
Nogo-A/mouse line have been described before (Simonen et al., 2003;
Dimou et al., 2006). Nogo-A was absent in the knock-outs, as expected
(Fig. S1, available at www.jneurosci.org as supplemental material) (see
also Simonen et al., 2003; Dimou et al., 2006). The animals were housed
on a reversed 12/12 h light/dark cycle (lights on at 8:00 P.M.) under
temperature-controlled (21°C) and humidity-controlled (55%) condi-
tions and maintained under ad libitum food and water. Animals derived
from multiple litters were used for each experiment. All animals were
experimentally naive at the time of testing. Testingwas performed during
the dark phase of the light/dark cycle. All procedures described in the
present study had been approved by the Cantonal Veterinary Office in
Zurich and are in agreement with the Principles of Laboratory Animal
Care (National Institutes of Health publication no. 86-23, revised 1985).
Behavioral analysis
Elevated plus maze. The expression of spontaneous anxiety-like behavior
was assessed in the elevated plus maze test. Twomaze designs were used,
differing in whether the maze walls were opaque or transparent. Such
variation in the transparency of the closed arms has been suggested to be
more congenial for the detection of anxiolytic or anxiogenic traits, re-
spectively (Hagenbuch et al., 2006). The two mazes were identical in
dimensions, consisting of two open and two enclosed arms, radiating
from a central platform. Their construction has been fully described
before (Willi et al., 2009). The test began by placing the animal on the
central platform with its head facing one of the open arms. The mouse
was then left to freely explore the maze for 5 min. A digital camera was
mounted above the maze. Images were captured at a rate of 5 Hz and
transmitted to a personal computer running the Ethovision tracking
system (Noldus Technology). The following two indices of anxiety-
related behavior were computed: the percentage open-arm entries
[open-arm entries/(open-arm entries  closed-arm entries)  100%],
and the percentage time spent in the open arms [time in open arms/(time
in open arms time in closed arms) 100%]. In addition, total distance
traveled in the entire maze (in centimeters) was taken as a measure of
activity.
Open-field exploration. Spatial exploration was evaluated in four iden-
tical white open-field arenas (40  40 cm) as described previously
(Meyer et al., 2006). Animals were allowed to freely explore the open field
for 1 h. For the purpose of data collection, the arenas were conceptually
partitioned into two zones: a center zone in the middle of the arena
(measuring 13.5  13.5 cm) and a peripheral zone occupying the re-
maining area. Data collection was performed using the Ethovision track-
ing system. The dependentmeasures were as follows: distance traveled in
the entire open-field arena and number of entries into the central area of
the open field, expressed as a function of 5 min bins.
Prepulse inhibition. Prepulse inhibition (PPI) refers to the reduction in
startle reaction to a startle-eliciting pulse stimulus when it is shortly
preceded by a subthreshold prepulse stimulus (Hoffman and Searle,
1965). A test of PPI was conducted using four acoustic startle chambers
(SR-LAB, San Diego Instruments), in which the startle reflex was trig-
gered by a 40 ms 120 dBA white noise pulse stimulus. The test apparatus
and procedures have been fully described before (Meyer et al., 2005).
Inhibition of the pulse-elicited startle reflex was achieved by using 20 ms
white noise prepulse stimuli of various intensities (69, 73, 77, 81, and 85
dBA) that preceded the pulse stimulus by 100ms. PPI was indexed by the
percentage inhibitionof the startle responseat each levelofprepulse intensity
by the following formula:% PPI [1 (mean reactivity on prepulse-plus-
pulse trials/mean reactivity on pulse-alone trials)] 100%.
Latent inhibition. Latent inhibition (LI) refers to the retardation in
learning about the significance of a stimulus as a result of its prior re-
peated pre-exposures without consequence (Lubow and Moore, 1959).
LI was assessed in a conditioned freezing paradigm using two sets of four
chambers as previously described (Meyer et al., 2005). The test proce-
dures consisted of four phases: pre-exposure, conditioning, context test,
and tone test. Animals were randomly allocated to either the pre-exposed
or non-pre-exposed condition. Pre-exposed animals received 40 presen-
tations of a 30 s tone stimulus at a variable interstimulus interval of 40
30 s, while non-pre-exposed animalswere confined to the chamber for an
equivalent time. Conditioning followed immediately at the end of pre-
exposure without removing the animals from the chambers. Condition-
ing contained three discrete trials of tone–shock pairings. Each trial
beganwith the 30 s tone stimulus followed immediately by the delivery of
a 1 s footshock (0.25mA). Each trial was preceded and followed by a 180 s
interval. The context test took place 24 h later, when the subjects were
returned to the same chambers for a period of 480 s in the absence of any
discrete stimulus. The tone test was conducted another 24 h later in the
same test chamber to assess the conditioned response to the tone. Fol-
lowing a 180 s acclimatization period, the tone was continuously pre-
sented for 180 s, and freezing (immobility) in the presence of the tone
stimulus was evaluated. Freezing was expressed as the percentage time
freezing for all test sessions.
Active avoidance learning. The active avoidance learning task captures
elements of both classical and instrumental conditioning, in which the
animals learned to perform a specific operant act in response to a tone
stimulus to avoid the delivery of an aversive footshock. The apparatus
consisted of four identical two-way shuttle boxes as fully described before
(Yee et al., 2006). Electric shocks (0.3mA) could be delivered through the
grid floor. The conditioned stimulus (CS) was an 86 dBA tone. Animals
were placed in the shuttle chambers and received a total of 100 condi-
tioned avoidance trials presented with an intertrial interval of 40 15 s.
A trial began with the onset of the tone. If the animal shuttled within 5 s
of tone onset, the tonewas terminated and the animal avoided the electric
shock on that trial. Avoidance failure led immediately to an electric foot-
shock presented in coincidence to the tone. This lasted for amaximumof
2 s but could be terminated earlier by a shuttle response during this
period (i.e., an escape response). To index conditioned avoidance learn-
ing, the mean number of avoidance shuttles performed across successive
20-trial blocks was calculated. To account for general locomotor activity,
the number of spontaneous shuttles performed during the intertrial in-
tervals was also analyzed.
Discrimination reversal learning. Discrimination reversal learning was
examined using a water T-maze. The apparatus and procedures have
been fully described before (Meyer et al., 2006). In acquisition training,
the animals were required to learn to discriminate the left and right goal
arms, with only one of them leading to an escape platform hidden just
beneath the water surface at the far end. There were six trials per daily
session, conducted at an intertrial interval of 10min. Acquisition training
continued until an animal had reached the criterion performance of 11
correct responses across 2 consecutive days. To assess reversal learning,
the platform location was then moved to the other, previously incorrect,
arm from the following day onwards. Reversal training continued until
an animal had achieved criterion performance again. The percentage of
correct arm choices per day was recorded for each animal during acqui-
sition and reversal training.
Social interaction and social novelty. Social behavior was assessed using
methods adapted from previous studies (Smith et al., 2007; Moy et al.,
2009). The testing apparatus comprised a rectangular, three-chambered
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Plexiglas box (61 40.5 cm). The chambers were separated by dividing
walls, which had openings (6 4 cm) that allowed the animals to move
between them. The doorways could be blocked by removable partitions.
Cylindrical wire grid cages (10 cm height, 11 cm bottom diameter, bars
horizontally and vertically spaced 9 mm apart) carrying a weighted cup
on top of the cage to prevent the test mice from climbing and remaining
on top of the wire cage were placed in each of the two side chambers. The
test procedures consisted of three 10 min phases: habituation, social
interaction, and social novelty. For habituation, each mouse was placed
into the center compartment and allowed to freely explore the entire box.
After this initial habituation period, the animalwas enclosed in the center
compartment, and an unfamiliar, adult C57BL/6J male mouse (stranger
1) was placed in one of the wire cages, whereas a dummymouse was put
into the other one. The doors were then reopened, and the animal was
allowed to explore the three chambers. The location of the stranger and
the dummy mouse alternated between the left and the right chambers
across subjects. At the end of this social interaction test, the preference of
each mouse for social novelty was assessed. The test animal was enclosed
in the center chamber, and the dummy mouse was replaced by a novel
unfamiliarmouse (stranger 2). The test animal was then again allowed to
explore the entire box. For all test sessions, the time spent in each cham-
ber and the time spent sniffing each cage (i.e., nose detection within a
circular area of 10 mm in diameter surrounding the cage) were recorded
using the Ethovision XT tracking system.
Amphetamine-induced locomotor activity. The test for amphetamine-
induced hyperlocomotor activity was conducted in the open-field appa-
ratus described above. Animals were first allowed to explore the arena for
30 min, were then injected with vehicle solution (isotonic 0.9% NaCl
solution, intraperitoneally, injection volume of 5 ml/kg), and were im-
mediately returned to the same arena for 30 min. Subsequently, the
animals were administered with D-amphetamine sulfate (2.5 mg/kg, in-
traperitoneally, injection volumeof 5ml/kg) and the locomotor response
to the acute drug challenge was observed over a period of 120 min. Data
collection was performed using the Ethovision tracking system. The dis-
tance traveled in the entire open-field arena was recorded and expressed
as a function of 5 min bins.
High-performance liquid chromatography
Postmortem neurochemical analyses using high-performance liquid
chromatography (HPLC)were performed as previously described (Enard et
al., 2009;Winter et al., 2009).The levelsofmonoaminesdopamine (DA)and
serotonin (5-HT) and their metabolites dihydroxyphenylacetic acid
(DOPAC), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid
(5-HIAA) in various brain areas were measured by HPLC with electro-
chemical detection. Glutamate, GABA, glutamine, and taurine levels in
the same brain regions were determined by HPLC with fluorescence
detection.
Immunohistochemistry
Tissue preparation. Animals were deeply anesthetized with pentobarbital
(Nembutal, 40 mg/kg body weight, intraperitoneally; Abbott Laborato-
ries) and transcardially perfused with PBS (pH 7.4, room temperature),
followed by ice-cold fixative [4% paraformaldehyde and 15% saturated
picric acid in 0.15 M phosphate buffer (PB), pH 7.4] as described previ-
ously (Fritschy and Mohler, 1995). Brains were removed immediately
after perfusion, postfixed in the same fixative for 4 h at 4°C, and im-
mersed in 10%, 20%, and then 30% sucrose diluted in PBS for cryopro-
tection before freezing. Coronal sections (40 m) were cut with a
cryostat-microtome (model MGW Lauda 1720, Leitz) and collected in
PBS. Sections were then transferred into antifreeze solution (15% su-
crose and 30% ethylene glycol in 50mMPB, pH 7.4) and stored at20°C
until used. Before immunostaining, sections for some antigen stainings
were then processed with modified antigen retrieval protocols to opti-
mize the signal-to-noise ratio (Table S1, available at www.jneurosci.org
as supplemental material).
Immunostaining. Free-floating, bregma-matched sections fromNogo-
A/ andNogo-A/mice were coded and batch processed under iden-
tical conditions tominimize staining variability. Sections were incubated
overnight at 4°C with primary antibodies (Table S1, available at www.
jneurosci.org as supplemental material) diluted in PBS containing 4%
normal goat serum and 0.05% Triton X-100. For GAP-43, S100, and
GFAP stainings, sections were then rinsed with 0.1 M PB and probed with
fluorescence-conjugated secondary antibodies coupled to Cy2 or Cy3
(Jackson ImmunoResearch Laboratories). For DA D2 receptor (D2R)
staining, primary antibodies were detected with biotinylated anti-
body, washed with PB, and probed with streptavidin Cy3 (Jackson
ImmunoResearch Laboratories). For cytoarchitectonic reference,
some sections were counterstained with Hoechst or NeuroTrace 640/
660 deep-red fluorescent Nissl stain (Invitrogen). Sections were
mounted on gelatin-coated slides, air dried, and finally coverslipped
with Mowiol (Calbiochem).
Densitometry. Microscopic analyses were conducted under strictly
blind conditions. Images were acquired using a cooled CCD camera
(CoolSnap HQ, Photometrics) attached to a Zeiss Axiophot microscope
(Zeiss) and collected using computer-assisted image analysis software
(MCID, Elite Software version 7.0, Imaging Research). For each animal,
the marker immunoreactivity (IR) in a given region was obtained from
bilateral densitometric measurements per section and evaluated using
the software ImageJ (NIH, Bethesda, MD). The background-corrected
optical densities were averaged per brain region and animal. The mean
relative optical densities of the wild-type animals were set as 1.0 for each
marker and brain region. For confirmation of the observed findings in
some markers at higher magnification and their representative illustra-
tion, imageswere also acquiredwith a spectral confocalmicroscope (TCS
SP2 AOBS, LeicaMicrosystems); only identical minimal contrast adjust-
ments were applied.
D2R IRwas evaluated in themedial prefrontal cortex (including layers
II/III and V/VI of cingulate cortices 1/2), caudate–putamen, and nucleus
accumbens core and shell. Digital images were acquired using a 20
objective (NA 0.5) and pixel brightness was measured in each brain area
of interest by placing three or four rectangular boxes of 160 200m in
the respective areas in both hemispheres. IRs for GAP-43, S100, and
GFAP were investigated in the medial prefrontal cortex, caudate–puta-
men, nucleus accumbens core and shell, CA1 (including all layers), CA3
(including all layers), and dentate gyrus (including granular and molec-
ular layers). Digital images were acquired using a 10 objective (NA 0.3)
and pixel brightness was measured in each brain area of interest by plac-
ing three or four rectangular boxes of 325  400 m in the respective
areas in both hemispheres.
Analysis after acute Nogo-A neutralization in adult mice
Experimental groups. Two cohorts of adultNogo-A/mice treated with
either anti-Nogo-A or control antibodies were used to assess whether
acute blockade ofNogo-A function could induce changes similar to those
observed after lifelong absence of Nogo-A function in the Nogo-A/
mice. One cohort of mice was tested in the amphetamine-induced loco-
motor activity task. The second cohort was examined for D2R and
GAP-43 expression. As antibody availability was limited, we focused on
these particular analyses only. Behavioral and immunohistochemical
analyses were conducted after 2 weeks of antibody treatment.
Pump implantation and application of antibodies. Mice were deeply
anesthetized with Hypnorm (30 l/20 g of body weight; 0.315 mg of
fentanyl citrate and 10 mg of fluanisone per ml; VetaPharma) and Dor-
micum (60l/20 g of body weight; 5mg ofMidazolamumperml; Roche
Pharmaceuticals). A hole was drilled into the dorsal lamina of the second
lumbar vertebra, through which a fine catheter (32 G; Recathco) was
inserted into the intrathecal space and pushed up to T10. The catheter
was connected to the outlet of an osmotic minipump (AlzetModel 1002,
Charles River Laboratories), whichwas placed under the skin on the back
and filled with 600g of monoclonal anti-Nogo-A antibody (11C7) (for
details, see the study by Weinmann et al., 2006) or control monoclonal
IgG antibody (directed against the plant protein wheat auxin) (see also
Weinmann et al., 2006) in PBS, to deliver a constant amount of antibod-
ies into the CSF for at least up to 2 weeks. The anti-Nogo-A antibody
11C7 is monospecific for Nogo-A on Western blots and does not cross-
react with other Nogo splice variants (Dodd et al., 2005). Pumps and
antibody delivery to spinal cord and brain were verified at the end of the
experiments. Infused antibodies were detected by immunoperoxidase
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staining and the use of anti-IgG antibodies (see also Weinmann et al.,
2006).
Statistical analysis
Behavioral data were subjected to parametric ANOVAof the appropriate
design. Data interpretation was further assisted by Fisher’s least signifi-
cant difference post hoc comparisons and the use of restricted ANOVAs
whenever appropriate. HPLC and immunohistochemical data were an-
alyzed using independent Student’s t tests (two tailed). All statistical
analyses were conducted using the statistical software SPSS forWindows
(release 14.0).
Results
Schizophrenia-like behavioral phenotype inNogo-A
knock-out mice
In 2- to 4-month-old adult mice, we first examined the effect of
genetic Nogo-A deletion on behavioral functions that are consid-
ered to be relevant to schizophrenia endophenotypes or overt
psychopathology.
Anxiety-related behavior and spontaneous locomotor activity
were examined in the elevated plus maze and the open-field ex-
ploration tests. For the interpretation of the data derived from the
aversive conditioning paradigms, it is essential to ascertain
whether the Nogo-A deletion had any effects on unconditioned
anxiety-like behavior and spontaneous locomotor activity. Addi-
tionally, heightened anxiety has been found to be associated with
schizophrenia (Lewis andLieberman, 2000). In the twodesigns of
the elevated plus maze test used here, no differences in anxiety-
related behavior were detected between genotypes, as measured
by the percentage of open-arm entries or the percentage of time
spent in the open arms. Nogo-A/ (n  9/maze) and Nogo-
A/ (n 10/maze) mice displayed a mean percentage of open-
arm entries of 32.5  3.2% versus 28.0  4.1% (opaque maze)
and 46.5 3.2% versus 43.5 2.7% (transparent maze), respec-
tively. The mean percentage of time spent in the open arms was
14.0 3.2% versus 9.7 1.9% (opaque maze) and 29.5 5.6%
versus 32.5  4.9% (transparent maze), respectively. Examina-
tion of locomotion as measured by total distance traveled in the
maze further indicated that the groups behaved similarly to each
other (opaque maze, 1097.0 69.7 cm versus 1151.7 38.7 cm;
transparent maze, 1108.9  56.1 cm versus 1074.2  37.4 cm).
Spatial exploration in the open field was
analyzed by focusing on the number of
entries the animals ventured into the cen-
tral area of the arena.Nogo-A/ (n 10)
and Nogo-A/ (n  14) mice showed
similar values on this measure (11.4 1.3
versus 8.9  1.1 entries per 5 min bin,
respectively). Overall locomotor activity
as indicated by the distance traveled in the
entire open field also did not differ be-
tween the groups (1341.8  79.8 cm ver-
sus 1232.0  67.0 cm per 5 min bin,
respectively).
Sensorimotor gating was assessed by
testing PPI. PPI deficiency has been linked
to several neuropsychiatric disorders with
a presumed neurodevelopmental origin,
including schizophrenia and autism
(Braff et al., 2001; Perry et al., 2007). As
expected, the level of prepulse inhibition
increased with increasing prepulse inten-
sity (prepulse intensity: F(4,88)  27.75,
p  0.001). Nogo-A/ mice displayed
clearly reduced PPI (percentage inhibi-
tion) independent of prepulse intensity compared with Nogo-
A/ mice (genotype: F(1,22)  5.24, p  0.05) (Fig. 1A).
Consistent with previous findings (Willi et al., 2009), neither startle
reactivity responses recordedonpulse-alone (Fig. 1B) nor prepulse-
alone trials (data not shown) were significantly altered in Nogo-
A/mice, thus confirming that Nogo-A deletion did not result in
any general hearing or startle reflex impairment.
Latent inhibition is a form of selective associative learning
reported to be impaired in schizophrenic patients (Baruch et al.,
1988; Gray et al., 1992). In the conditioned freezing paradigm
used to assess LI here, the development of conditioned freezing
was evaluated across the three tone–footshock pairings (Fig. 2A).
LI was evident by elevated freezing levels in the non-pre-exposed
animals relative to the pre-exposed animals (pre-exposure: F(1,44)
21.48, p  0.001). Although the LI effect appeared weaker in
Nogo-A/ relative toNogo-A/mice, the interaction between
pre-exposure and genotype did not attain statistical significance
(F(1,44) 2.20, p 0.145). The expression of conditioned freez-
ing to the context was evaluated 24 h after conditioning (Fig. 2B).
Contextual freezing was generally low in all groups and was not
affected by the Nogo-A deletion. In the test of the conditioned
response to the tone 48 h after conditioning in the same chambers
(Fig. 2C), the presence of LI in Nogo-A/ mice was demon-
strated by a clear reduction in the amount of freezing to the tone
in the pre-exposed animals relative to the non-pre-exposed ones.
In contrast, LI was substantially attenuated in Nogo-A/mice.
This impression was supported by the presence of the significant
interaction between pre-exposure and genotype (F(1,44)  5.99,
p  0.05). Subsequent post hoc comparisons confirmed that a
significant presence of LI was only statistically evident in Nogo-
A/mice ( p 0.001). It is apparent that the disruption of the LI
effect seen in the Nogo-A/ mice was mainly attributed to in-
creased tone-freezing in the pre-exposed condition, compared
with Nogo-A/ mice. Additional analyses restricted to either
pre-exposure condition revealed thatNogo-A/mice displayed
significantly higher freezing levels than Nogo-A/ mice in the
pre-exposed condition (genotype: F(1,22)  6.31, p  0.05),
whereas both non-pre-exposed groups were comparable. In the 3
min before tone onset, freezing was generally low, with mutant
Figure1. Decreasedprepulse inhibition inNogo-A/mice.A, PPI is indexedby thepercentagePPI at eachprepulse intensity.
The histogram on the right illustrates the overall means across all prepulse intensities. Magnitude of the percentage PPI increased
with increasing prepulse intensity. Nogo-A/ mice displayed reduced PPI compared with Nogo-A/ mice (*p  0.05).
B, Startle reactivity topulse-alone trials in arbitraryunits. Therewasno significantdifferencebetween thegenotypes. All values are
mean SEM. KO, Nogo-A/ (n 12); WT, Nogo-A/ (n 12).
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and control mice not differing in their overall level of freezing
regardless of pre-exposure condition.
To further verify that the disrupted LI seen in Nogo-A/
mice is unlikely to be due to a general impairment in the acqui-
sition of a conditioned response, another associative learning
paradigm (i.e., active avoidance) was conducted. Acquisition of
the conditioned avoidance response was evident in both groups
as indicated by the increase in the number of avoidance responses
over successive 20-trial blocks (blocks:F(4,88) 83.50, p 0.001).
Consistent with the outcome of the conditioned freezing experi-
ment, no significant group difference was detected (Fig. S2A,
available at www.jneurosci.org as supplemental material). In
agreementwith the results obtained in the elevated plusmaze and
open-field tests, spontaneous locomotor activity (asmeasured by
the number of spontaneous shuttles performed during the inter-
trial interval periods) did not differ between genotypes (Fig. S2B,
available at www.jneurosci.org as supplemental material).
Behavioral flexibility was then evaluated in a discrimination
reversal learning task using a water T-maze. A learning deficit
specific to the reversal phase, in the absence of an initial acquisi-
tion deficit, is indicative of perseverative behavior, as implicated
in schizophrenia and autism (Ridley, 1994). Performance during
the initial acquisition phase did not differ between genotypes,
indicating that there is no general learning deficit after Nogo-A
deletion (Fig. 3). In the reversal phase, Nogo-A/ mice exhib-
ited behavioral perseveration as evidenced by impaired choice accu-
racy compared with control mice (genotype days: F(7,210) 2.56,
p  0.05). As shown in Figure 3, the initial impact of reversal was
comparablebetween thegroups,but its influenceonchoicebehavior
had a higher impact on Nogo-A/ animals, as they were more
slowly adapting to the reversed contingency.
Next, social behavior was examined. Social withdrawal is a
characteristic that can be found in both schizophrenia and autism
(American Psychiatric Association, 2000). In the social interac-
tion assay, the animals generally spent more time in the chamber
containing the stranger mouse (stranger 1) versus the chamber
containing the dummy mouse (chambers: F(1,20)  20.70, p 
0.001), and this effect was not dependent on the genotype (Fig.
4A). In the social novelty preference assay, a significant prefer-
ence for spending time in the chamber with the novel stranger
(stranger 2) versus the chamber with the familiar stranger
(stranger 1) was observed (chambers: F(1,20) 10.84, p 0.01).
Again, this effect did not depend on the genotype (Fig. 4B). Anal-
ysis of time spent sniffing each cage during both test phases (data
not shown) yielded consistent results comparedwith the data on the
time spent in each respective chamber, supporting the view that
social behavior is similar inNogo-A/ andNogo-A/mice.
To clarify whether Nogo-A/ mice possess a psychotic-like
phenotypic profile, we tested the locomotor stimulant effect of
the indirect DA-receptor agonist amphetamine – a drug known
to exacerbate and induce psychotic symptoms in humans (Laruelle
et al., 1996). In a novel open field, locomotor activity for the
baseline period and after vehicle (saline) injection was similar
between genotypes (Fig. 5). Systemic administration of amphet-
amine resulted in markedly increased locomotor activity in both
Nogo-A/ and Nogo-A/ mice (bins: F(23,368)  33.37, p 
Figure2. Impaired latent inhibition inNogo-A/mice.A, Expressionof freezingbehavior
toward the tone CS across the three conditioning trials immediately after pre-exposure in the
conditioned freezing paradigm. Freezing is expressed as the percentage time freezing per trial.
Freezing in the pre-exposed (PE) subjects was lower than in the non-pre-exposed (NPE) sub-
jects, constituting the LI effect. B, Freezing to the context 24 h after conditioning. This is ex-
pressed as the overall mean percentage time freezing. There was no effect of genotype or
pre-exposure. C, Freezing to the tone CS 48 h after conditioning. Freezing is expressed as the
mean percentage time freezing before tone onset on the left and as themean percentage time
freezing across the tone period on the right. In the 3min before the onset of the tone, therewas
nodifferencebetweenanyof thegroups for the levels of freezing. Reduced freezing levels to the
tone in the PE group compared with the NPE group in Nogo-A/ animals indicates the pres-
ence of LI (***p 0.001 based on a priori contrast). In contrast, Nogo-A/ mice failed to
show significant LI. This difference between the genotypes was supported by the presence of a
significant two-way interaction between pre-exposure and genotype ( p 0.05). Moreover,
there was a genotype effect in the PE condition (*p 0.05), whereas both NPE groups were
comparable. All values aremean SEM. KO,Nogo-A/ (n 9 PE, 9 NPE);WT,Nogo-A/
(n 15 PE, 15 NPE).
Figure 3. Emergence of perseverative behavior in Nogo-A/mice. Discrimination rever-
sal learning in thewater T-maze. Performance is expressed as the percentage correct responses
per day. Acquisition of the left–right discrimination learning was similar between the geno-
types. A reversal effect was evident in both groups as suggested by the below-chance perfor-
mance (represented by the dashed line) on the first day of the subsequent reversal training.
However, Nogo-A/ mice displayed a clear deficit in reversal learning as evidenced by a
significant genotype day interaction ( p 0.05). All values are mean SEM. **p 0.01,
***p 0.001 based on post hoc pairwise comparisons. KO, Nogo-A/ (n 16); WT, Nogo-
A/ (n 16).
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0.001). However, the drug-induced hyperactivity was signifi-
cantly more pronounced in Nogo-A/ animals, particularly in
the first half of the 120 min test session (genotype: F(1,16) 5.71,
p 0.05, genotype bins: F(23,368) 2.09, p 0.01) (Fig. 5).
Alterations in brain dopamine and serotonin inNogo-A
knock-out mice
To investigate putative changes after Nogo-A deletion at the neu-
rotransmitter level, specific anatomical regions were microdis-
sected from fresh frozen brain slices and analyzed by HPLC.
Levels of DA and its metabolites DOPAC and HVA were signifi-
cantly reduced (DA:62%, p 0.001;DOPAC:55%, p 0.01;
HVA: 55%, p  0.01) in the dorsal striatum (i.e., caudate–
putamen) of Nogo-A/ mice. In the medial prefrontal cortex,
the ventral striatum (i.e., nucleus accumbens), and the hip-
pocampus, basal contents of DA and its metabolites were not
affected by Nogo-A deletion (Table 1).
Contents of 5-HT and its metabolite 5-HIAA were significantly
reduced in the dorsal striatum (5-HT:75%, p 0.001; 5-HIAA:
90%, p  0.001) of Nogo-A/ mice. In addition, Nogo-A/
mice displayed lower 5-HT levels in the hippocampus (27%, p
0.05). In contrast, Nogo-A deletion did not affect basal 5-HT and
5-HIAA contents in the medial prefrontal cortex (Table 1).
To further assess the impact of Nogo-A deletion on mono-
amine turnover in the adult brain, the ratios of DOPAC/DA,
HVA/DA, and 5-HT/5-HIAA were analyzed (Table 1). DA turn-
over was significantly increased in themedial prefrontal cortex of
Nogo-A/ mice (DOPAC/DA: 136%, p  0.05; HVA/DA:
144%, p  0.05). 5-HT turnover was significantly reduced in
the dorsal striatum (60%, p  0.01) of Nogo-A/ mice. No
other changes in DA or 5-HT turnover were detected.
Glutamate and GABA levels were not significantly altered in
Nogo-A/mice in any of the brain regions examined. Similarly,
contentsof glutamineand the inhibitory aminosulfonic acid taurine
were not altered in the brain of Nogo-A/mice (Table 2).
Changes of dopamine D2 receptor expression inNogo-A
knock-out brain
Next, we evaluated whether the observed alterations in DA levels
and turnover in the striatum and the me-
dial prefrontal cortex ofNogo-A/mice
were paralleled by changes in the expres-
sion of the D2R, a receptor suggested to
play an important role in the pathophysi-
ology of schizophrenia, as most of the
commonly used neuroleptics block this
receptor (Seeman, 1987). Nogo-A dele-
tion decreased D2R-IR in the medial pre-
frontal cortex (34%, p 0.05), whereas
it led to an elevation ofD2R-IR in the dor-
sal striatum (i.e., caudate–putamen;
27%, p 0.01). In the ventral striatum
(i.e., nucleus accumbens), D2R-IR was
similar between Nogo-A/ and Nogo-
A/mice (Fig. 6).
Increased expression of GAP-43 and
S100B inNogo-A knock-out brain
To seek further concomitant structural
modifications in Nogo-A/ brain, we
examined putative changes in growth-
related markers. We focused on the
growth-associated protein GAP-43 and
S100B, because elevations of both markers have been repeatedly
reported in brains of schizophrenic patients (Perrone-Bizzozero
et al., 1996; Blennow et al., 1999; Rothermundt et al., 2004).
Moreover, GAP-43 expression was also found to be transiently
upregulated after acute antibody-mediated Nogo-A neutraliza-
tion in the intact adult rat CNS (Bareyre et al., 2002), and S100B
is thought to exert some of its effects by inhibition of phosphor-
ylation of synaptic and growth proteins such as GAP-43 (Sheu et
al., 1994). IR for GAP-43 was significantly elevated in the medial
prefrontal cortex (24%, p  0.05), the dentate gyrus (31%,
p 0.05), and the hippocampal CA1 region (10%, p 0.05) of
Nogo-A/ mice, but remained unaltered in the hippocampal
CA3 region and both dorsal and ventral striatum (Fig. 7A,B,E).
Similar to GAP-43, S100-IR was elevated in themedial prefrontal
cortex (31%, p 0.01) and the dentate gyrus (22%, p 0.05)
of Nogo-A/ mice, whereas its levels were comparable in the
hippocampal subfields CA1 and CA3, and both dorsal and ven-
Figure 4. Social interaction and social novelty preference levels are similar in Nogo-A/
and Nogo-A/ mice. A, Social interaction is indexed by the time spent in the compartment
containing a strangermouse (stranger 1) versus the time spent in the compartment containing
a dummymouse. There was a general preference for the stranger mouse. No significant differ-
ence between the genotypes was detected. B, Time spent in the compartment containing a
novel strangermouse (stranger 2) versus the first strangermouse (stranger 1) during the social
novelty task. There was a general preference for the novel stranger mouse. No significant dif-
ference between the genotypes was detected. All values are mean SEM. KO, Nogo-A/
(n 11); WT, Nogo-A/ (n 11).
Figure 5. Increased sensitivity to the motor stimulant effects of systemic amphetamine in Nogo-A/ mice. Locomotor
activity in the open field is expressed as distance traveled per 5 min bin. The inset on the right illustrates the overall means across
the amphetamine period. Locomotor activity for the baseline period and after vehicle (SAL, saline) injection was similar between
both groups. Systemic administration of amphetamine (AMPH) resulted in a general increase in locomotor activity. The locomotor
effect to thedrugwaspotentiated inNogo-A/mice comparedwithNogo-A/mice (*p0.05). All values aremeanSEM.
*p 0.05, **p 0.01, ***p 0.001 in the line plot based on post hoc pairwise comparisons. KO, Nogo-A/ (n 9); WT,
Nogo-A/ (n 9).
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tral striatum between Nogo-A/ and Nogo-A/ mice (Fig.
7C,D,F).
Increased S100-IR identified in specific brain regions inNogo-
A/mice was not associated with higher levels of the astrocyte
marker GFAP, thus suggesting that Nogo-A deletion did not in-
duce reactive gliosis (Fig. 8).
Absence of abnormal phenotype in mice treated with
anti-Nogo-A antibodies in adulthood
Finally, we performed some of the major analyses described
above in anti-Nogo-A versus control antibody-treated adult
Nogo-A/ mice. Lack of effects after such acute blockade of
Nogo-A function would support the hypothesis that neurodevel-
opmental aberrations due to Nogo-A deficiency in early life
underlie the Nogo-A knock-out phenotypes, as would be antici-
pated based on the neurodevelopmental hypothesis of schizo-
phrenia (Weinberger, 1987; Harrison, 1997; Lewis and Levitt,
2002; Rapoport et al., 2005). Twoweeks of
continuous intrathecal delivery of the
function-blocking monoclonal mouse
antibody 11C7 led to high levels of anti-
body throughout the brain and spinal
cord (Fig. 9A–D), very similar to earlier
studies in rats and macaque monkeys
(Weinmann et al., 2006). Following
amphetamine treatment, control and
anti-Nogo-A antibody-treated groups
displayed a similar hyperlocomotor re-
sponse (Fig. 9E). Histologically, IRs for
D2R were highly comparable in all
regions of interest between the two
groups (Fig. 9F–H ). In contrast, expres-
sion of GAP-43 was found to be slightly
increased after anti-Nogo-A antibody
treatment in the dentate gyrus (12%,
p  0.05), but it was not altered in hip-
pocampal subfields CA1/CA3, the me-
dial prefrontal cortex, and both dorsal
and ventral striatum (Fig. S3, available
at www.jneurosci.org as supplemental
material).
Discussion
This study represents the first systematic attempt to assess the
impact of genetic Nogo-A deficiency on schizophrenia-asso-
ciated traits and has identified multiple relevant phenotypes in
Nogo-A/ mice in terms of behavior, pharmacology, and
neurochemistry.
Across a battery of translational behavioral paradigms rele-
vant for assessing face validity of animal models of schizophrenia
(Lipska andWeinberger, 2000; Arguello andGogos, 2006; Powell
Figure 6. Selective changes in D2R immunoreactivity in Nogo-A/mice. A–D, Representative images of immunostaining
withD2R in themedial prefrontal cortex (A,B) and thedorsal striatum (C,D) ofNogo-A/ andNogo-A/mice.E, Quantitative
analysis of the D2R staining. The relative optical density of D2R was reduced in the medial prefrontal cortex (mPFC; *p 0.05)
ofNogo-A/mice, whereas it was elevated in the dorsal striatum (CPu; **p 0.01). No changes were observed in the nucleus
accumbens core (NAcC) and shell (NAcS) regions. Note the differences in staining intensity between the striatum and the medial
prefrontal cortexwith the typically high levels in the striatum. All values aremean SEM. Scale bars:A,B, 50m; C,D, 100m.
KO, Nogo-A/ (n 6–7); WT, Nogo-A/ (n 6–7).
Table 1. Alterations in brainmonoamine levels and turnover in Nogo-A/mice
DA DOPAC HVA DOPAC/DA HVA/DA 5-HT 5-HIAA 5-HIAA/5-HT
mPFC
WT 9.26 1.58 1.01 0.43 3.65 1.53 0.11 0.05 0.31 0.12 73.95 9.26 41.52 6.77 0.59 0.10
KO 6.50 0.70 1.50 0.29 4.69 0.77 0.25 0.05* 0.75 0.12* 64.43 6.28 56.48 14.61 0.85 0.18
CPu
WT 1001.63 124.89 63.29 8.52 87.57 13.93 0.06 0.00 0.09 0.00 64.89 9.18 63.80 9.57 1.03 0.13
KO 378.72 38.04*** 28.76 3.88** 39.77 4.81** 0.08 0.01 0.11 0.02 16.55 1.76*** 6.29 2.34*** 0.42 0.14**
NAc
WT 373.93 50.33 45.58 7.55 46.46 7.55 0.12 0.00 0.12 0.01 174.83 19.65 94.56 9.53 0.60 0.10
KO 322.99 26.33 48.92 5.56 47.22 4.80 0.16 0.02 0.15 0.02 129.63 9.40 64.80 9.04 0.50 0.11
HPC
WT 6.43 0.66 ND 2.55 0.93 ND 0.41 0.16 90.78 7.94 102.09 18.44 1.18 0.23
KO 5.93 0.69 ND 3.05 1.11 ND 0.62 0.31 66.15 6.77* 84.52 15.12 1.90 0.85
Levels are expressed asmean concentrations in nmol/mg protein. All values aremean SEM. *p 0.05, **p 0.01, ***p 0.001. mPFC, Medial prefrontal cortex; CPu, caudate-putamen; NAc, nucleus accumbens; HPC, hippocampus;
ND, not detectable; KO, Nogo-A/ (n 6–9); WT, Nogo-A/ (n 8–10).
Table 2. Brain glutamate, glutamine, taurine, and GABA levels in Nogo-A/ and
Nogo-A/mice
GLU GLN TAU GABA
mPFC
WT 108.46 5.28 40.73 7.20 87.06 3.77 15.55 1.03
KO 101.05 1.62 31.86 4.31 84.34 4.26 14.05 0.36
CPu
WT 84.84 6.24 45.76 7.81 113.05 6.42 15.07 1.23
KO 76.10 2.58 35.53 3.62 103.61 5.63 13.75 0.50
NAc
WT 74.26 6.06 53.11 6.96 70.97 6.33 54.48 1.89
KO 65.58 2.14 42.74 5.36 66.44 3.37 45.40 3.64
HPC
WT 87.68 5.22 41.58 6.64 83.52 4.52 23.90 1.37
KO 81.68 3.32 34.13 4.36 77.44 4.41 21.04 0.98
Levels are expressed asmean concentrations in nmol/mg protein. All values are mean SEM. GLU, Glutamate;
GLN, glutamine; TAU, taurine; mPFC, medial prefrontal cortex; CPu, caudate-putamen; NAc, nucleus accumbens;
HPC, hippocampus; KO, Nogo-A/ (n 8–10); WT, Nogo-A/ (n 8–10).
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andMiyakawa, 2006),Nogo-A/mice displayed deficits in both
PPI and LI, indicating disruptions in sensorimotor gating and
selective attention that are related to the symptoms (especially
positive) of schizophrenia (Baruch et al., 1988; Braff et al., 2001).
Nogo-A/ mice also exhibited perseverative behavior in dis-
crimination reversal, resembling another neuropsychological
sign in schizophrenia (Crider, 1997). Furthermore, the motor
stimulant response to systemic amphetamine in the open field
was substantially potentiated in thesemice, consolidating a similar
finding obtained under familiar home cage conditions (Willi et al.,
2009). Notably, enhanced susceptibility to acute amphetamine
treatment has been directly linked to the genesis of positive symp-
toms in schizophrenia (Laruelle et al., 1996). On the other hand,
spontaneous anxiety-like behavior as well as social behavior were
not affected in theNogo-A/mice. The latter is commonly used
to model negative symptoms of schizophrenia in rodents. Con-
stitutive knock-out of Nogo-A therefore produces a spectrum of
selective behavioral and psychopharmacological aberrations in
adulthood that are related to schizophrenia traits. Domains re-
lated primarily to the positive and cognitive symptoms of schizo-
phrenia appear affected. The list of used tasks is not exhaustive, of
course, as there are other tests that could be performed.
In light of the range of behavioral changes in Nogo-A/
mice, it is not surprising that major neurochemical changes were
identified in different striatal and limbic structures, and the ob-
served neurochemical consequences of this constitutive Nogo-A
absence may readily contribute to some of the behavioral and
psychopharmacological dysfunctions present in Nogo-A/
mice. For example, increased D2R expression in the dorsal stria-
tum constitutes a condition that could well lead to the enhanced
sensitivity to amphetamine seen in Nogo-A/ mice (Wolinsky
et al., 2007). Decreased basal DA levels in the dorsal striatum per
se might rather predict an attenuation of amphetamine activa-
tion, but upregulation of D2R in this brain area may represent a
compensatory mechanism and shift the balance to higher am-
phetamine reactivity. It has been postulated that an overactive
DA transporter system and alterations in other regulatory mech-
anismsmay lead to a reduction in basal striatal DA and ultimately
to upregulation of DA receptors (Grace, 1993; Salahpour et al.,
2008). Similar mechanisms may be responsible for the enhanced
amphetamine-induced locomotor activation in Nogo-A/
mice. In addition, D2R downregulation in the medial prefrontal
cortex of Nogo-A/ mice could also contribute to this pheno-
type, given that infusions of DA receptor agonists into themedial
prefrontal cortex can block amphetamine-induced hyperactivity
(Broersen et al., 1999). Furthermore, D2R downregulation seen
in Nogo-A/ mice is consistent with D2R antagonist infusion
into the medial prefrontal cortex attenuating PPI (Ellenbroek et
al., 1996). One should notice that the deficiency in 5-HT and its
metabolite 5-HIAA in Nogo-A/ mice may also contribute to
the precipitation of the PPI deficit (Prinssen et al., 2002) and the
increased sensitivity to systemic amphetamine (Marek, 2007).
Additional studies are clearly warranted to further dissect the
relative contributions of distinct neurochemical abnormalities to
behavioral and pharmacological dysfunctions in mice lacking
Nogo-A. One possibility would be to test whether the PPI and
amphetamine phenotypes may be preferentially normalized by
DA antagonists versus selective 5-HT reuptake inhibitors.
Given the substantial alterations revealed in specific DA cir-
cuits after constitutive Nogo-A deletion, it is crucial to assess the
extent to which these DA changes are consistent with the DA
pathophysiology identified in schizophrenia. Elevations of D2R
densities in the striatum (Wong et al., 1986; Seeman, 1987; Seeman
and Kapur, 2000; Hirvonen et al., 2005) and decreased levels of
D2R in extrastriatal regions (Takahashi et al., 2006) have been
reported in schizophrenic patients and correlate very well with
our results in Nogo-A/ mice. The dorsal striatal reduction in
DA content in Nogo-A/ mice may seem surprising. This ap-
pears to be inconsistent with the dopaminergic hypothesis of
schizophrenia in terms of directional and regional selectivity, as
Figure 7. Increased immunoreactivity of GAP-43 and S100 in Nogo-A/mice. A–D, Representative images of immunostaining with GAP-43 (A, B) and S100 (C, D) in the dentate gyrus of
Nogo-A/ and Nogo-A/mice. E, F, Quantitative analysis of the respective stainings. The relative optical density of GAP-43 was enhanced in the medial prefrontal cortex (mPFC; *p 0.05),
the dentate gyrus (DG; *p 0.05), and the CA1 region (*p 0.05) of Nogo-A/mice, whereas it was not altered in the CA3 region, the dorsal striatum (CPu), and the nucleus accumbens core
(NAcC) and shell (NAcS) regions (E). Similarly, S100 immunoreactivitywas elevated in themPFC (**p0.01) andDG (*p0.05) ofNogo-A/mice, but itwas not altered in the other brain areas
investigated (F ). All values are mean SEM. Scale bar, 200m. KO, Nogo-A/ (n 6–8); WT, Nogo-A/ (n 5–8).
Figure 8. No indication of reactive gliosis inNogo-A/mice.A,B, Representative images
of immunostaining with the astrocyte marker GFAP in the dentate gyrus of Nogo-A/ and
Nogo-A/mice. C, Quantitative analysis of the GFAP staining. No difference between Nogo-
A/ andNogo-A/micewas detected in the relative optical density of GFAP. All values are
mean SEM. Scale bar, 200 m. DG, Dentate gyrus; mPFC, medial prefrontal cortex; CPu,
dorsal striatum; NAcC, nucleus accumbens core; NAcS, nucleus accumbens shell; KO, Nogo-
A/ (n 4–6); WT, Nogo-A/ (n 4–6).
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increased dopaminergic activity localized to the ventral striatum
is thought to be critical for schizophrenia (Seeman and Kapur,
2000). However, DA transmission is orchestrated by a broad net-
work of brain areas, and disturbed mental functioning in schizo-
phrenia is more likely attributable to complex dysregulations in
multiple interconnected brain regions rather than a singular uni-
directional change in a specific neurotransmitter (Grace, 1993;
O’Donnell and Grace, 1998; Carlsson et al., 2001; Carlsson,
2006). One also has to keep in mind that Nogo-A/ mice
showed 5-HT deficits and a potential modulatory role for 5-HT
in schizophrenia pathophysiology has been suggested (Abi-
Dargham, 2007). However, it is important to emphasize that our
knowledge of neuropathological disease markers in humans, and
thus their availability in rodents, is limited. The claim of definite
links between neurochemical markers and symptoms or behav-
ioral phenotypes, respectively, is therefore complicated.
To date, it is not known whether Nogo-A is directly involved
in dopaminergic transmission or related mechanisms. The fact
that DA systems are affected after constitutive Nogo-A deletion is
nonetheless not surprising. Interestingly, maturation of the dif-
ferent dopaminergic systems follows distinct developmental pro-
gression with differential temporal windows (Sturrock, 1980;
Voorn et al., 1988), and wiring of dopaminergic projection sys-
tems appears to be extremely susceptible to neurodevelop-
mental insults. Various genetic as well as environmental
manipulations, even when they are not directly targeting the
dopaminergic systems, can lead to profound and specific long-
term disturbances within distinct dopaminergic circuits
(Roffler-Tarlov and Graybiel, 1984; Lipska et al., 2003; Fone
and Porkess, 2008; Meyer et al., 2008; Winter et al., 2009).
Thus, the defects in DA and its metabolites in Nogo-A/
mice could well originate from selective, yet unknown, dys-
functions occurring during brain development. This would be
in line with a role for Nogo-A in brain wiring processes during
development (McGee et al., 2005; Mingorance-Le Meur et al.,
2007).
During development, Nogo-A is present in early migrating
neurons and during neurite outgrowth; Nogo-deficient mice
show changes in cortical development and neuronal maturation
(Mingorance-Le Meur et al., 2007). Aberrant neuronal develop-
ment in cortical and subcortical areas due to the lack of neuronal
Nogo-A might therefore contribute to the development of the
behavioral and neurochemical changes described here, as seen in
schizophrenia (Weinberger, 1987; Harrison, 1999; Ross et al.,
2006) and several neurodevelopmental models of this disease in
animals (e.g., Shen et al., 2008). In addition, increased expression
levels of the growth-related proteins GAP-43 and S100B mainly
in the medial prefrontal cortex and dentate gyrus of Nogo-A/
mice suggest that lifelong absence of Nogo-A may lead to abnor-
mal growth, entailing perturbed neurodevelopment (McGee et
al., 2005). Growth dysregulations are likely due to the lack of
Nogo-A inmyelin (Schwab, 2004;McGee et al., 2005), which is in
keeping with the notion that myelin-related abnormalities, such
as lack of myelin-based restriction of axonal plasticity particularly
duringdevelopment, contributes to the risk of schizophrenia (Davis
et al., 2003; Karoutzou et al., 2007). Although transitory suppres-
sion of Nogo-A function by antibodies applied to adult mice
slightly increased GAP-43 expression in the dentate gyrus, this
elevation was less pronounced than in Nogo-A/mice and did
not affect behavior. It is also important to highlight that there was
no indication of neurodegeneration in Nogo-A/ mice as evi-
denced by the absence of reactive gliosis. Together, our data are
consistent with the suggestion of developmental changes and dys-
regulated fiber growth and plasticity in the animals chronically
lacking Nogo-A as one generic mechanism for the development of
schizophrenia-like symptoms. This hypothesized association is
highly interesting in view of a recent report linking schizophrenia to
deficientNogo/NgR1signalingassociatedwitha failure in restricting
anatomical plasticity (Budel et al., 2008).
While the absence of major abnormalities in animals treated
with anti-Nogo-A antibodies in adulthood may indicate that
neurodevelopmental factors could play a role in the genesis of the
Figure 9. Absence of schizophrenia-like abnormalities in adult mice acutely treated with anti-Nogo-A antibodies for 2 weeks. A–C, Comparative regional antibody distribution in cervical spinal
cord after intrathecal lumbar delivery of anti-Nogo-A or control IgG antibody via osmoticminipumps. Color coding of sections processed for immunoperoxidase staining ranges fromblack/dark blue,
for background, to violet, red, orange, yellow, and white, for maximal staining intensity. Note the clear difference in antibody levels between the treatment groups. D, Representative image of
antibodydetection in the cortexof ananti-Nogo-Aantibody-treatedanimal. Stained cell bodies reflect uptakeofNogo-A–anti-Nogo-Aantibody complexesas shownearlier (Weinmannetal., 2006).
E, Sensitivity of mice to the motor stimulant effects of systemic amphetamine. Locomotor activating effect of amphetamine is expressed as overall mean distance traveled during the 120 min
observationperiod. Anti-Nogo-Aantibody treatment didnot significantly affect the locomotor reactivity to thedrug (n9/group).F,G, Representative images of D2R immunostaining in thedorsal
striatum of mice treated with either anti-Nogo-A or control antibodies. H, Quantitative analysis of the D2R staining. The relative optical density of D2R in the medial prefrontal cortex (mPFC), the
dorsal striatum (CPu), and the nucleus accumbens core (NAcC) and shell (NAcS) regions, was not affected by the anti-Nogo-A antibody treatment (n 5/group). All values aremean SEM. Scale
bars: A–C, 0.5 mm; D, 20m; F, G, 100m. 11C7, Anti-Nogo-A antibody treated; IgG, control IgG treated; no pump, no pump control.
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Nogo-A knock-out phenotypes, one cannot exclude the possibil-
ity that the loss of Nogo-A in the adult brain as such could not
contribute to their emergence. A rescue experiment by reintro-
ducing Nogo-A into the knock-out mice would help to answer
this question. Alternatively, examining the impact of Nogo-A
blockade during early neurodevelopmental stages on brain func-
tion in the adult would also be highly instructive. Several critical
time windows in fetal and early postnatal brain development
would have to be taken into account in this respect, however (see
Keshavan and Hogarty, 1999; Meyer et al., 2007). Because the
feasibility of antibody pump implantations inmice is limited and
its application in developing animals not possible, the generation
of temporally controlled Nogo-A knock-out mice using specific
gene induction systems (Wang et al., 1994; Kistner et al., 1996)
would be necessary. Nevertheless, the fact that a transient loss of
Nogo-A function in the adult CNS was not associated with
schizophrenia-like effects is of utmost importance with regard to
the ongoing clinical trials using function-blocking agents for
Nogo-A in spinal cord injured patients.
In conclusion, the present study shows that Nogo-A is rele-
vant for a wide spectrum of brain and behavioral functions. This
implies an important role for Nogo-A in development in general,
regardless of whether such behavioral, anatomical, and neuro-
chemical differences faithfully mimic schizophrenic symptoms.
Our findings thus bear broader significance for other neurode-
velopmentalmental disorders such as autism. This geneticmouse
model holds additional heuristic value in elucidating the relevant
neurodevelopmental, epigenetic, and physiological mechanisms
thatmight be sensitive to Nogo-A polymorphisms. Characteriza-
tion of relevant molecular pathways would also be instrumental
in the identification of novel drug targets for therapeutic and
protective interventions.
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